Discovery of Next-Generation Antibody Candidates and Generation of New Programs
First written in FY2021. 13 of 18 entries say "Restated". Latest entry: 2026-08-13.
4 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「For next-generation drug discovery, the company is developing efficient antibody acquisition technologies, building its database using the new PPMX Antibody Library 2, and acquiring antibodies against challenging antigens through its proprietary AI drug-discovery technology.」
The company is continuing to acquire antibodies against challenging antigens using improved PPMX Antibody Library 2, its database and proprietary AI drug-discovery technology. As no new achievements were reported, this was treated as a reconfirmation. - FY2025AdvancedAnnual report
「During the current fiscal year, the company successfully created PPMX Antibody Library 2, an improved version of its phage library. Using this library, the company will develop its database and use its proprietary AI drug-discovery technology to acquire antibodies against challenging antigens that are difficult to target.」
The successful creation of improved PPMX Antibody Library 2 has established the next-stage discovery approach of developing a database and using AI drug discovery to acquire antibodies against challenging antigens. - FY2025-H1RestatedAnnual report
「In addition, the company is continuing to develop antibody acquisition technologies to improve efficiency and improve its phage library for next-generation drug discovery.」
The company is continuing to develop antibody acquisition technologies and improve its phage library for next-generation drug discovery. - FY2024-Q2RestatedAnnual report
「In addition, the company is continuing to develop efficient antibody acquisition technologies and improve its phage library for next-generation drug discovery.」
The company is continuing to develop antibody acquisition technologies and improve its phage library for next-generation drug discovery. - FY2024-Q1RestatedAnnual report
「In addition, the company is continuing to develop efficient antibody acquisition technologies and improve its phage library for next-generation drug discovery.」
The company is continuing to develop antibody acquisition technologies and improve its phage library for next-generation drug discovery. - FY2023RestatedAnnual report
「The company is conducting ongoing collaborative research with multiple university research institutions and collecting evaluation data on candidate targets. It is also actively introducing new technologies for generating antibodies against those targets and will further advance research into discovering new antibody drug seeds.」
The company is continuing to collect evaluation data on candidate targets, introduce new technologies and conduct research into discovering new antibody drug seeds. - FY2023-Q3RestatedAnnual report
「Many additional antibody candidates are in the research and development stage.」
The company reconfirmed that many antibody candidates following the lead pipeline are in the research and development stage. - FY2023-Q2RestatedAnnual report
「Many additional antibody candidates are in the research and development stage.」
The company reconfirmed that many antibody candidates following the lead pipeline are in the research and development stage. - FY2023-Q1RestatedAnnual report
「Many additional antibody candidates are in the research and development stage.」
The company reconfirmed that many antibody candidates following the lead pipeline are in the research and development stage. - FY2022-Q3RestatedAnnual report
「Many additional antibody candidates are in the research and development stage.」
The company reconfirmed that many antibody candidates following the lead pipeline are in the research and development stage. - FY2022-Q2RestatedAnnual report
「Many additional antibody candidates are in the research and development stage.」
The company reconfirmed that multiple antibody candidates following the lead pipeline are in the research and development stage. - FY2022-Q1RestatedAnnual report
「Many additional antibody candidates are in the research and development stage.」
The company disclosed that many antibody candidates following the lead pipeline are in the research and development stage. - FY2021First statedAnnual report
「The company will obtain basic data on multiple next-generation development candidate antibodies and clarify the next development candidates. It will also continue acquiring new antibodies to generate development candidates.」
The company is using the acquisition of basic data on multiple candidates and the continued acquisition of new antibodies to build its next pipeline.